Some examples of this are that not all HER2-positive breast cancer patients respond well to anti-HER2 therapies; or in the case of “benign” proliferative conditions, patients with similar diagnoses often exhibit variable responses to hormonal treatments. Here, ERBB2 is linked to breast carcinoma.